Gyon Technologies Capital Management LP Raises Position in CTI BioPharma Corp.

CTICDelisted Stock  USD 9.09  0.00  0.00%   
About 56% of CTi Biopharma's investor base is looking to short. The analysis of current outlook of investing in CTi Biopharma Corp suggests that many traders are alarmed regarding CTi Biopharma's prospects. The current market sentiment, together with CTi Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use CTi Biopharma Corp stock news signals to limit their universe of possible portfolio assets.
  
Gyon Technologies Capital Management LP raised its position in CTI BioPharma Corp. by 138.2 percent during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 192,831 shares of the biopharmaceutical companys stock after acquiring an additional 111,891 shares during the quarter. Gyon Technologies

Read at thelincolnianonline.com
news
  

CTi Biopharma Fundamental Analysis

We analyze CTi Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTi Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTi Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Gross Profit

Gross Profit Comparative Analysis

CTi Biopharma is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

CTi Biopharma Corp Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CTi Biopharma stock to make a market-neutral strategy. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics with similar companies.

Peers

CTi Biopharma Related Equities

PDSBPDS Biotechnology   4.65   
0%
56.0%
MDGLMadrigal Pharmaceuticals   0.88   
0%
10.0%
CRVSCorvus Pharmaceuticals   0.36   
0%
4.0%
IMMPImmutep   1.46   
17.0%
0%
PLXProtalix Biotherapeutics   1.80   
21.0%
0%
RIGLRigel Pharmaceuticals   2.03   
24.0%
0%
VSTMVerastem   2.36   
28.0%
0%
VKTXViking Therapeutics   2.43   
29.0%
0%
RVPHReviva Pharmaceuticals   3.23   
39.0%
0%
FBIOFortress Biotech   4.78   
57.0%
0%
TGTXTG Therapeutics   4.84   
58.0%
0%
XFORX4 Pharmaceuticals   5.13   
62.0%
0%
MCRBSeres Therapeutics   5.38   
65.0%
0%
CDTXCidara Therapeutics   5.60   
67.0%
0%
ELEVElevation Oncology   8.06   
97.0%
0%
IBRXImmunitybio   8.25   
100.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in CTi Stock

If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio